Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perflenapent SCHEMBL7648533 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL984715 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL3743142 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1924377 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| Perflexane SCHEMBL3671912 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1707474 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| Perflexane SCHEMBL7507426 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1779065 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL771546 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 | |
| Perflexane SCHEMBL20769778 | 1.00 | LMNA (0.61) | LMNATHRBCA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144875-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS THERAPEUTICS LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739312-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS Therapeutics LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260124305-A1 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | ADS THERAPEUTICS LLC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4706766-A2 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | ADS Therapeutics LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12485177-B2 | Topical ophthalmological compositions | ADS THERAPEUTICS LLC (US) | 2025-12-02 | — | — | US | claimed |
| EP-4225284-B1 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | ADS THERAPEUTICS LLC (US) | 2025-11-26 | — | — | EP | claimed |
| US-20250345287-A1 | COMPOSITION COMPRISING A MIXTURE OF AT LEAST ONE OIL AND ONE OR MORE SEMIFLUORINATED ALKANES, A USE OF THE COMPOSITION FOR TREATING A DISEASE AS WELL AS A METHOD OF PRODUCING THE COMPOSITION AND CORRESPONDING KITS | FLUORON GMBH (DE) | 2025-11-13 | — | — | US | claimed |
| EP-4647066-A1 | A COMPOSITION COMPRISING A MIXTURE OF AT LEAST ONE OIL AND ONE OR MORE SEMIFLUORINATED ALKANES, A USE OF THE COMPOSITION FOR TREATING A DISEASE AS WELL AS A METHOD OF PRODUCING THE COMPOSITION AND CORRESPONDING KITS | Fluoron GmbH (DE) | 2025-11-12 | — | — | EP | claimed |
| EP-4637775-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS Therapeutics LLC (US) | 2025-10-29 | — | — | EP | claimed |
| CN-105142681-B | Semi-fluorocarbon containing contrast agents | 贝朗医疗有限公司 | 2019-03-12 | — | — | CN | claimed |
| CN-107677615-A | The detection method of particulate matter content in a kind of fluorine-containing alkane | 上海杰视医疗科技有限公司 | 2018-02-09 | — | — | CN | claimed |
| EP-2978455-B1 | SEMIFLUOROCARBON COMPOUND CONTAINING CONTRAST AGENT | BRAUN MELSUNGEN AG (DE) | 2017-01-04 | — | — | EP | claimed |
| EP-2978455-A1 | SEMIFLUOROCARBON COMPOUND CONTAINING CONTRAST AGENT | B. Braun Melsungen AG (DE) | 2016-02-03 | — | — | EP | claimed |
| US-20160000941-A1 | Semifluorocarbon Compound Containing Contrast Agent | B. BRAUN MELSUNGEN AG (DE) | 2016-01-07 | — | — | US | claimed |
| CN-105142681-A | Semi-fluorocarbon containing contrast agents | BRAUN MEDICAL INC | 2015-12-09 | — | — | CN | claimed |
| WO-2014154531-A1 | SEMIFLUOROCARBON COMPOUND CONTAINING CONTRAST AGENT | B. BRAUN MELSUNGEN AG (DE) | 2014-10-02 | — | — | WO | claimed |
| EP-2783703-A1 | Semifluorocarbon compound containing contrast agent | B. Braun Melsungen AG (DE) | 2014-10-01 | — | — | EP | claimed |
| EP-2730291-A1 | Internal Tamponade Composition | FLUORON GMBH (DE) | 2014-05-14 | — | — | EP | claimed |
| US-4100037-A | Method of depositing a metal on a surface | WESTERN ELECTRIC COMPANY, INC. (US) | 1978-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000941-A1 | Semifluorocarbon Compound Containing Contrast Agent | LIPC, LIPA, CETP | LMNA 977/4885THRB 2275/4885CA2 1926/4885 |
| US-12485177-B2 | Topical ophthalmological compositions | CHRM3, CYSLTR1, CHRM5 | LMNA 2469/4885THRB 62/4885CA2 2271/4885 |
| US-20260124305-A1 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | CHRM5, FFAR3, CHRM2 | LMNA 2553/4885THRB 53/4885CA2 2160/4885 |
| US-20260130896-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | CHRM5, CHRM3, CHRM2 | LMNA 2401/4885THRB 223/4885CA2 1000/4885 |
| US-20260144875-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | STRA6, RBP4, F12 | LMNA 3320/4885THRB 305/4885CA2 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.